ArticleNature communications2024
Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
13.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Diagnostic value of blood p-tau subtypes in Alzheimer's disease progression and pathology: systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- Tau dysfunction in alzheimer's disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives.Molecular biology reports · 2026Review
- CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum.EBioMedicine · 2026Article
- Review
- DYRK1A and Parkinson's disease, facts and hypotheses.Neurobiology of disease · 2026Review
- Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.Acta neuropathologica · 2026Article
- Blood-Based Biomarkers Predict Differential Longitudinal Decline in Alzheimer's Disease Psychosis: Evidence from Two Cohorts.medRxiv : the preprint server for health sciences · 2026Article
- Tau pathological activity in plasma before the onset of symptomatic Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026Article
- Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.Alzheimer's research & therapy · 2026Article
- Review
- Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology.Journal of neurology · 2025Article
- Fluid biomarkers for neurodegenerative diseases: a comprehensive update.Alzheimer's research & therapy · 2025Review
- Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.Genomic psychiatry : advancing science from genes to society · 2025Article
- Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease.Journal of neurochemistry · 2025Article
- Post-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use.Clinical chemistry · 2025Review
- Adipokines at the Metabolic-Brain Interface: Therapeutic Modulation by Antidiabetic Agents and Natural Compounds in Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers.Biosensors · 2025Review
Corrections and comments
- Update of
Authors and funding
33 authors at 13 institutions in 7 countries.
Przemysław R KacDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden. przemyslaw.kac@gu.se.ORCID http://orcid.org/0000-0001-5083-0924
Fernando González-OrtizDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0001-7897-9456
Andreja EmeršičDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
Maciej DulewiczDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0002-7149-017X
Srinivas KoutarapuDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
Michael TurtonBioventix Plc, Farnham, GU9 7SX, UK.
Yang AnBrain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.
Denis SmirnovDepartment of Neurosciences, University of California, San Diego, CA, 92161, USA.
Agnieszka Kulczyńska-PrzybikDepartment of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland.
Vijay R VarmaClinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.ORCID http://orcid.org/0000-0001-7143-7726
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
Laia Montoliu-GayaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
Elena CamporesiDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
Izabela WinkelDementia Disorders Center, Medical University of Wrocław, 59-330, Ścinawa, Poland.
Bogusław ParadowskiDepartment of Neurology, Medical University of Wrocław, 50-556, Wrocław, Poland.
Abhay MoghekarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Juan C TroncosoDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Tammaryn LashleyDepartment of Neurodegenerative diseases, UCL Queen Square Institute of Neurology, WC1N 1PJ, London, UK.ORCID http://orcid.org/0000-0001-7389-0348
Gunnar BrinkmalmDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0001-6958-2393
Susan M ResnickLaboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.ORCID http://orcid.org/0000-0003-1115-7145
Barbara MroczkoDepartment of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland.
Hlin KvartsbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0002-4481-508X
Milica Gregorič KrambergerDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
Jörg HanriederDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0001-6059-198X
Saša ČučnikDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
Peter HarrisonBioventix Plc, Farnham, GU9 7SX, UK.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0003-3930-4354
Piotr LewczukDepartment of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland.
Madhav ThambisettyClinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.ORCID http://orcid.org/0000-0002-2200-2299
Uroš RotDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, CA, 92161, USA.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0002-1890-4193
Thomas K KarikariDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.ORCID http://orcid.org/0000-0003-1422-4358
University of Gothenburg · SENational Institutes of Health · USUniversity of Ljubljana · SIMedical University of Białystok · PLSahlgrenska University Hospital · SEJohns Hopkins University · USUniversity of California San Diego · USUniversity of Wrocław · PLKing's College London · GBNational Hospital for Neurology and Neurosurgery · GBUK Dementia Research Institute · GBUniversity of Pittsburgh · USUniversity of Wisconsin–Madison · US
Funding
Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Milos D Ikonomovic · 2005 to 2026
$56.5MLongitudinal multicenter head-to-head harmonization of tau PET tracersR01AG073267 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKER, SUZANNE L, PASCOAL, THARICK · 2021 to 2025
$41.1MUCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9MResearch Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN · 2020 to 2026
$29.4MResearch Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3MInvestigating Gains in Neurocognition in an Intervention Trial of Exercise SupplementR01AG053952 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BURNS, JEFFREY MURRAY, ERICKSON, KIRK I · 2016 to 2020
$27.5MEarly Markers of Alzheimer DiseaseZIAAG000185 · NIA · NATIONAL INSTITUTE ON AGING · PI WALKER, KEENAN · 2009 to 2025
$20.4MMild Cognitive Impairment: A Prospective Community StudyR37AG023651 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Carmen Andreescu, MARY GANGULI · 2021 to 2026
$18.2MPlasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5MThe RAW Brain - The Effect of Rumination, Anxiety and Worry on Aging and Dementia RiskR01MH108509 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Carmen Andreescu · 2016 to 2026
$10.6MPredictors of Altered CNS Structure, Function, and Connectomics in the Elderly using a Health Disparities FrameworkR01AG072641 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ann D. Cohen · 2022 to 2026
$9.6MSubclinical vascular disease and AD pathology in the transition from midlife to old ageRF1AG052525 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L., REIS, STEVEN E · 2018 to 2018
$9.3MAlzheimer's Association #AARF-21-850325NIA NIH HHS P01 AG025204NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066507NIA NIH HHS R01 AG025516NIA NIH HHS R01 AG053952NIA NIH HHS R01 AG068398NIA NIH HHS R01 AG072641NIA NIH HHS R01 AG073267NIA NIH HHS R01 AG075336NIA NIH HHS R01 AG078796NIA NIH HHS R01 AG083874NIA NIH HHS R21 AG078538NIA NIH HHS R21 AG080705NIA NIH HHS R37 AG023651NIA NIH HHS RF1 AG025516NIA NIH HHS RF1 AG052525NIA NIH HHS U24 AG082930NIMH NIH HHS R01 MH108509NIMH NIH HHS R01 MH121619
Abstract
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n = 388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a peripherally accessible biomarker of AD pathophysiology.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesAutopsyBiomarkersHumansNeurofibrillary TanglesNeuropathologyPlasmatau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.